Sabinsa Granted Patent for Forskolin Process

The New Zealand Patent Office has granted a patent to Sabinsa for processes to prepare derivatives of forskolin, namely, isoforskolin and 7-deacetylforskolin.

NZ Patent No: 568652 'Commercial Process for Making Forskolin and its Derivatives' will be in force until February 2, 2027.

This most recent patent is #63 in Sabinsa...s worldwide Intellectual Property portfolio. Additionally, Sabinsa has more than 50 pending patent applications worldwide. This patent furthers Sabinsa...s ability to protect their Intellectual Property as they make inroads into Oceania. The company recently received Product Information (PI) numbers for ForsLean 10% and 20% from Australia...s TGA (Therapeutic Goods Administration), a division of the Australian Government Department of Health and Ageing, opening the way for ForsLean to enter the Australian market.

Press release by Sabinsa